{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:07:04Z","timestamp":1782274024236,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,10,16]],"date-time":"2014-10-16T00:00:00Z","timestamp":1413417600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s11095-014-1546-5","type":"journal-article","created":{"date-parts":[[2014,10,15]],"date-time":"2014-10-15T14:51:33Z","timestamp":1413384693000},"page":"1417-1424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Noninvasive Sampling of Gabapentin by Reverse Iontophoresis"],"prefix":"10.1007","volume":"32","author":[{"given":"Anroop B.","family":"Nair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachna","family":"Kumria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bandar E.","family":"Al-Dhubiab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Attimarad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sree","family":"Harsha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,16]]},"reference":[{"issue":"3","key":"1546_CR1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1474-4422(05)70020-X","volume":"4","author":"A Jacoby","year":"2005","unstructured":"Jacoby A, Snape D, Baker GA. Epilepsy and social identity: the stigma of a chronic neurological disorder. Lancet Neurol. 2005;4(3):171\u20138.","journal-title":"Lancet Neurol"},{"key":"1546_CR2","unstructured":"WHO, World Health Organization Epilepsy: Key facts. Available at: www.who.int\/mediacentre\/factsheets\/fs999\/en Accessed June 3, 2014."},{"issue":"7","key":"1546_CR3","first-page":"392","volume":"35","author":"MM Goldenberg","year":"2010","unstructured":"Goldenberg MM. Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment. Proc Natl Acad Sci U S A. 2010;35(7):392\u2013415.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1546_CR4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/2042098611411127","volume":"2","author":"JA French","year":"2011","unstructured":"French JA, Gazzola DM. New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? Ther Adv Drug Saf. 2011;2(4):141\u201358.","journal-title":"Ther Adv Drug Saf"},{"issue":"5","key":"1546_CR5","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/S0149-2918(03)80127-3","volume":"25","author":"MJ McLean","year":"2003","unstructured":"McLean MJ, Gidal BE. Gabapentin dosing in the treatment of epilepsy. Clin Ther. 2003;25(5):1382\u2013406.","journal-title":"Clin Ther"},{"key":"1546_CR6","first-page":"CD001415","volume":"7","author":"S Al-Bachari","year":"2013","unstructured":"Al-Bachari S, Pulman J, Hutton JL, Marson AG. Gabapentin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2013;7:CD001415.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1546_CR7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.0003-2409.2001.02399.x","volume":"57","author":"MA Rose","year":"2002","unstructured":"Rose MA, Kam PC. Gabapentin: pharmacology and its use in pain management. Anaesthesia. 2002;57(5):451\u201362.","journal-title":"Anaesthesia"},{"key":"1546_CR8","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/00003088-200645110-00002","volume":"45","author":"SI Johannessen","year":"2006","unstructured":"Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet. 2006;45:1061\u201375.","journal-title":"Clin Pharmacokinet"},{"key":"1546_CR9","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3390\/ph3061909","volume":"3","author":"MD Krasowski","year":"2010","unstructured":"Krasowski MD. Therapeutic drug monitoring of the newer anti-epilepsy medications. Pharmaceuticals. 2010;3:1909\u201335.","journal-title":"Pharmaceuticals"},{"issue":"4","key":"1546_CR10","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1528-1157.1991.tb04689.x","volume":"32","author":"J Sivenius","year":"1991","unstructured":"Sivenius J, K\u00e4lvi\u00e4inen R, Ylinen A, Riekkinen P. Double-blind study of Gabapentin in the treatment of partial seizures. Epilepsia. 1991;32(4):539\u201342.","journal-title":"Epilepsia"},{"key":"1546_CR11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00007691-200306000-00016","volume":"25","author":"SI Johannessen","year":"2003","unstructured":"Johannessen SI, Battino D, Berry DJ, Bialer M, Kr\u00e4mer G, Tomson T, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit. 2003;25:347\u201363.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"1546_CR12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/FTD.0b013e31827c11e7","volume":"35","author":"PN Patsalos","year":"2013","unstructured":"Patsalos PN, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs by use of saliva. Ther Drug Monit. 2013;35(1):4\u201329.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"1546_CR13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2515\/therapie\/2009069","volume":"65","author":"O Tribut","year":"2010","unstructured":"Tribut O, Bentu\u00e9-Ferrer D. Verdier MC; therapeutic drug monitoring of gabapentin. Therapie. 2010;65(1):57\u201360.","journal-title":"Therapie"},{"key":"1546_CR14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4103\/0976-0105.103825","volume":"3","author":"AB Nair","year":"2012","unstructured":"Nair AB, Goel A, Prakash S, Kumar A. Therapeutic drug monitoring by reverse iontophoresis. J Basic Clin Pharm. 2012;3:207\u201313.","journal-title":"J Basic Clin Pharm"},{"issue":"1","key":"1546_CR15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S1059131102001425","volume":"12","author":"DJ Berry","year":"2003","unstructured":"Berry DJ, Beran RG, Plunkeft MJ, Clarke LA, Hung WT. The absorption of gabapentin following high dose escalation. Seizure. 2003;12(1):28\u201336.","journal-title":"Seizure"},{"issue":"12","key":"1546_CR16","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1002\/jps.20989","volume":"96","author":"S Nixon","year":"2007","unstructured":"Nixon S, Sieg A, Delgado-Charro MB, Guy RH. Reverse iontophoresis of L-lactate: in vitro and in vivo studies. J Pharm Sci. 2007;96(12):3457\u201365.","journal-title":"J Pharm Sci"},{"issue":"1","key":"1546_CR17","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejpb.2008.12.012","volume":"72","author":"A Sieg","year":"2009","unstructured":"Sieg A, Jeanneret F, Fathi M, Hochstrasser D, Rudaz S, Veuthey JL, et al. Extraction of amino acids by reverse iontophoresis in vivo. Eur J Pharm Biopharm. 2009;72(1):226\u201331.","journal-title":"Eur J Pharm Biopharm"},{"key":"1546_CR18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1155\/2010\/284230","volume":"11","author":"Y Paulley","year":"2010","unstructured":"Paulley Y, Delgado-Charro MB, White KAJ. Modelling formation of a drug reservoir in the stratum corneum and its impact on drug monitoring using reverse iontophoresis. Comput Math Method M. 2010;11:353\u201368.","journal-title":"Comput Math Method M"},{"key":"1546_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/15569527.2010.517230","volume":"30","author":"CY Wang","year":"2011","unstructured":"Wang CY, Maibach HI. Why minimally invasive skin sampling techniques? a bright scientific future. Cutan Ocul Toxicol. 2011;30:1\u20136.","journal-title":"Cutan Ocul Toxicol"},{"key":"1546_CR20","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1088\/0967-3334\/25\/3\/R01","volume":"25","author":"B Leboulanger","year":"2004","unstructured":"Leboulanger B, Guy RH, Delgado CMB. Reverse iontophoresis for noninvasive transdermal monitoring. Physiol Meas. 2004;25:R35\u201350.","journal-title":"Physiol Meas"},{"issue":"2","key":"1546_CR21","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1570-0232(02)00399-9","volume":"779","author":"Z Zhu","year":"2002","unstructured":"Zhu Z, Neirinck L. High-performance liquid chromatographic method for the determination of gabapentin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;779(2):307\u201312.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"2","key":"1546_CR22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1773-2247(05)50025-X","volume":"15","author":"B Anroop","year":"2005","unstructured":"Anroop B, Ghosh B, Parcha V, Kumar A, Khanam J. Synthesis and comparative skin permeability of atenolol and propranolol esters. J Drug Del Sci Tech. 2005;15(2):187\u201390.","journal-title":"J Drug Del Sci Tech"},{"key":"1546_CR23","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3109\/10837450.2010.522585","volume":"17","author":"AB Nair","year":"2012","unstructured":"Nair AB, Vaka SR, Gupta S, Repka MA, Murthy SN. In vitro and in vivo evaluation of a hydrogel-based prototype transdermal patch system of alfuzosin hydrochloride. Pharm Dev Technol. 2012;17:158\u201363.","journal-title":"Pharm Dev Technol"},{"issue":"3","key":"1546_CR24","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","volume":"22","author":"S Reagan-Shaw","year":"2008","unstructured":"Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659\u201361.","journal-title":"FASEB J"},{"key":"1546_CR25","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/bdd.1866","volume":"34","author":"AB Nair","year":"2013","unstructured":"Nair AB, Singh K, Al-Dhubiab BE, Attimarad M, Harsha S, Alhaider IA. Skin uptake and clearance of ciclopirox following topical application. Biopharm Drug Dispos. 2013;34:540\u20139.","journal-title":"Biopharm Drug Dispos"},{"key":"1546_CR26","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2174\/156720109788680895","volume":"6","author":"B Anroop","year":"2009","unstructured":"Anroop B, Ghosh B, Parcha V, Khanam J. Transdermal delivery of atenolol: effect of prodrugs and iontophoresis. Curr Drug Deliv. 2009;6:280\u201390.","journal-title":"Curr Drug Deliv"},{"issue":"9","key":"1546_CR27","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3109\/10611860903089750","volume":"17","author":"A Sieg","year":"2009","unstructured":"Sieg A, Wascotte V. Diagnostic and therapeutic applications of iontophoresis. J Drug Target. 2009;17(9):690\u2013700.","journal-title":"J Drug Target"},{"issue":"6","key":"1546_CR28","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/bja\/aem316","volume":"99","author":"VK Kong","year":"2007","unstructured":"Kong VK, Irwin MG. Gabapentin: a multimodal perioperative drug? Br J Anaesth. 2007;99(6):775\u201386.","journal-title":"Br J Anaesth"},{"issue":"5","key":"1546_CR29","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1529\/biophysj.104.044792","volume":"87","author":"A Sieg","year":"2004","unstructured":"Sieg A, Guy RH, Delgado-Charro MB. Electroosmosis in transdermal iontophoresis: implications for noninvasive and calibration-free glucose monitoring. Biophys J. 2004;87(5):3344\u201350.","journal-title":"Biophys J"},{"issue":"7","key":"1546_CR30","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1023\/B:PHAM.0000033008.64915.c8","volume":"21","author":"B Leboulanger","year":"2004","unstructured":"Leboulanger B, Fathi M, Guy RH, Delgado-Charro MB. Reverse iontophoresis as a noninvasive tool for lithium monitoring and pharmacokinetic profiling. Pharm Res. 2004;21(7):1214\u201322.","journal-title":"Pharm Res"},{"issue":"3","key":"1546_CR31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1023\/A:1011050829531","volume":"18","author":"RF Lopez","year":"2001","unstructured":"Lopez RF, Bentley MV, Delgado-Charro MB, Guy RH. Iontophoretic delivery of 5-aminolevulinic acid (ALA): effect of pH. Pharm Res. 2001;18(3):311\u20135.","journal-title":"Pharm Res"},{"issue":"11","key":"1546_CR32","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1373\/clinchem.2004.034249","volume":"50","author":"B Leboulanger","year":"2004","unstructured":"Leboulanger B, Aubry JM, Bondolfi G, Guy RH, Delgado-Charro MB. Lithium monitoring by reverse iontophoresis in vivo. Clin Chem. 2004;50(11):2091\u2013100.","journal-title":"Clin Chem"},{"issue":"10","key":"1546_CR33","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.addr.2011.10.003","volume":"64","author":"C Johannessen Landmark","year":"2012","unstructured":"Johannessen Landmark C, Johannessen SI, Tomson T. Host factors affecting antiepileptic drug delivery-pharmacokinetic variability. Adv Drug Deliv Rev. 2012;64(10):896\u2013910.","journal-title":"Adv Drug Deliv Rev"},{"key":"1546_CR34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1600-0846.2009.00350.x","volume":"15","author":"A Nair","year":"2009","unstructured":"Nair A, Reddy C, Jacob S. Delivery of a classical antihypertensive agent through the skin by chemical enhancers and iontophoresis. Skin Res Technol. 2009;15:187\u201394.","journal-title":"Skin Res Technol"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-014-1546-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-014-1546-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-014-1546-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T05:51:14Z","timestamp":1559368274000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-014-1546-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,16]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["1546"],"URL":"https:\/\/doi.org\/10.1007\/s11095-014-1546-5","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,16]]}}}